Every recall we track for Mylan Institutional, Inc. — 9 in all — plus the complaints and injury reports the public filed about them.
Mylan recalls 150 mcg levothyroxine tablets due to potential super-potent drug potency. This may cause unsafe medication levels. Check NDC 51079-445-20 and lot 3116074 for affected units.
Mylan recalls 125 mcg levothyroxine tablets due to potential super-potent drug levels. Affected units may cause unsafe thyroid hormone levels if taken.
Mylan recalls 137 mcg levothyroxine tablets due to potential subpotent or superpotent drug levels. Affected units have specific NDC and expiration dates. Contact Mylan for remedy.
Mylan recalls 112 mcg levothyroxine tablets due to potential subpotent or superpotent drug levels. This may cause ineffective treatment or overmedication. Check NDC 42292-039-20 for affected units.
Mylan recalls 150 mcg levothyroxine tablets due to potential subpotent or superpotent drug levels. This may cause ineffective treatment or adverse effects. Check NDC 51079-445-20 for affected lots.
Mylan recalls 100-mcg levothyroxine tablets due to potential subpotent or superpotent drug levels. This may cause ineffective treatment or overmedication. No remedy specified in official notice.
Mylan recalls 175 mcg levothyroxine tablets due to potential subpotent or superpotent drug levels. This may cause ineffective treatment or adverse effects. Check NDC 42292-040-20 for affected lots.
Mylan recalls 125 mcg levothyroxine tablets due to potential subpotent or superpotent drug levels. This may cause ineffective treatment or overmedication. Check NDC 51079-443-20, lot 3115893, expiring 6/2025.
